Autonomix Medical presented new subgroup clinical data at the 2026 ASCO Gastrointestinal Cancers Symposium showcasing rapid, durable, and meaningful pain relief in pancreatic cancer patients across all disease stages.
The analysis revealed consistent pain reduction regardless of disease severity, even in late-stage patients with limited treatment options.
The findings reinforce the potential of targeted nerve-based treatments in providing relief beyond traditional options.
Rapid Pain Relief
Responding patients saw a marked reduction in pain within 24 hours post-procedure.
Sustained Benefit
Approximately two-thirds of patients maintained mild or eliminated pain levels at 4-6 weeks post-procedure.
Late-Stage Improvement
Meaningful pain relief was observed even in late-stage (Stage 4) pancreatic cancer patients.
Positive Clinical Impact
93.75% of patients showed improvement from severe pain to mild or moderate levels at 7 days post-procedure.
Palliative Potential
The study highlights the therapy's palliative impact in advanced pancreatic cancer, offering hope beyond standard care.
- Autonomix's clinical data showcased remarkable pain relief in pancreatic cancer patients regardless of disease stage.
- The findings suggest a promising alternative for patients with severe pain due to pancreatic cancer, addressing a critical unmet need in oncology care.
The presentation of Autonomix's study results signifies a significant advancement in pancreatic cancer pain management and highlights the potential of nerve-targeted treatments.